Teprotumumab Versus Intravenous Glucocorticoids in Thyroid Eye Disease: Insights from a Japanese MRI Study
Highlight
This Japanese real-world study demonstrates that teprotumumab significantly improves clinical manifestations of thyroid eye disease (TED), including proptosis, clinical activity, diplopia, and thyroid-stimulating antibody levels. Magnetic resonance imaging (MRI) reveals that teprotumumab reduces both extraocular muscle and orbital fat involvement, whereas intravenous glucocorticoid therapy (IVGC) reduces muscle inflammation but may increase orbital fat. Inflamed extraocular muscles identified by MRI are responsive to both therapies, underpinning their roles as critical treatment targets.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.